Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Sell
37
ICCC Quote, Financials, Valuation and Earnings
Last price:
$5.51
Seasonality move
:
10.13%
Day range:
$5.48 - $5.70
52-week range:
$4.28 - $7.60
Dividend yield:
0%
P/E ratio:
21.17x
P/S ratio:
1.78x
P/B ratio:
1.66x
Volume:
2.3K
Avg. volume:
20.4K
1-year change:
13.22%
Market cap:
$49.6M
Revenue:
$26.5M
EPS (TTM):
$0.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ICCC
ImmuCell Corp.
|
-- | -- | -- | -- | -- |
|
IDXX
IDEXX Laboratories, Inc.
|
$1.1B | $3.15 | 12.37% | 11.83% | $759.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ICCC
ImmuCell Corp.
|
$5.48 | -- | $49.6M | 21.17x | $0.00 | 0% | 1.78x |
|
IDXX
IDEXX Laboratories, Inc.
|
$706.65 | $759.00 | $56.4B | 56.02x | $0.00 | 0% | 13.83x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.55 | $0.85 | $195.3M | 2.60x | $0.80 | 0% | 3.01x |
|
OGEN
Oragenics, Inc.
|
$0.98 | $2.00 | $803K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.22 | $7.00 | $7.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ICCC
ImmuCell Corp.
|
31.35% | 0.769 | 24.07% | 1.61x |
|
IDXX
IDEXX Laboratories, Inc.
|
41.62% | 1.034 | 2.18% | 0.69x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ICCC
ImmuCell Corp.
|
$2.4M | $20.1K | 5.39% | 8.15% | 0.37% | -$1.8M |
|
IDXX
IDEXX Laboratories, Inc.
|
$685.3M | $356.8M | 39.29% | 66.88% | 32.28% | $357.9M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
ImmuCell Corp. vs. Competitors
-
Which has Higher Returns ICCC or IDXX?
IDEXX Laboratories, Inc. has a net margin of -2.54% compared to ImmuCell Corp.'s net margin of 24.85%. ImmuCell Corp.'s return on equity of 8.15% beat IDEXX Laboratories, Inc.'s return on equity of 66.88%.
Company Gross Margin Earnings Per Share Invested Capital ICCCImmuCell Corp.42.92% -$0.02 $43.4M IDXXIDEXX Laboratories, Inc.62.01% $3.40 $2.7B -
What do Analysts Say About ICCC or IDXX?
ImmuCell Corp. has a consensus price target of --, signalling upside risk potential of 155.48%. On the other hand IDEXX Laboratories, Inc. has an analysts' consensus of $759.00 which suggests that it could grow by 7.41%. Given that ImmuCell Corp. has higher upside potential than IDEXX Laboratories, Inc., analysts believe ImmuCell Corp. is more attractive than IDEXX Laboratories, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ICCCImmuCell Corp.0 0 0 IDXXIDEXX Laboratories, Inc.5 5 1 -
Is ICCC or IDXX More Risky?
ImmuCell Corp. has a beta of 0.200, which suggesting that the stock is 79.986% less volatile than S&P 500. In comparison IDEXX Laboratories, Inc. has a beta of 1.668, suggesting its more volatile than the S&P 500 by 66.77%.
-
Which is a Better Dividend Stock ICCC or IDXX?
ImmuCell Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IDEXX Laboratories, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmuCell Corp. pays -- of its earnings as a dividend. IDEXX Laboratories, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCC or IDXX?
ImmuCell Corp. quarterly revenues are $5.5M, which are smaller than IDEXX Laboratories, Inc. quarterly revenues of $1.1B. ImmuCell Corp.'s net income of -$139.7K is lower than IDEXX Laboratories, Inc.'s net income of $274.6M. Notably, ImmuCell Corp.'s price-to-earnings ratio is 21.17x while IDEXX Laboratories, Inc.'s PE ratio is 56.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmuCell Corp. is 1.78x versus 13.83x for IDEXX Laboratories, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCCImmuCell Corp.1.78x 21.17x $5.5M -$139.7K IDXXIDEXX Laboratories, Inc.13.83x 56.02x $1.1B $274.6M
-
Which has Higher Returns ICCC or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -2.54% compared to ImmuCell Corp.'s net margin of -255.85%. ImmuCell Corp.'s return on equity of 8.15% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital ICCCImmuCell Corp.42.92% -$0.02 $43.4M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About ICCC or NBY?
ImmuCell Corp. has a consensus price target of --, signalling upside risk potential of 155.48%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -45.16%. Given that ImmuCell Corp. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe ImmuCell Corp. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ICCCImmuCell Corp.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is ICCC or NBY More Risky?
ImmuCell Corp. has a beta of 0.200, which suggesting that the stock is 79.986% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock ICCC or NBY?
ImmuCell Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. ImmuCell Corp. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCC or NBY?
ImmuCell Corp. quarterly revenues are $5.5M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. ImmuCell Corp.'s net income of -$139.7K is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, ImmuCell Corp.'s price-to-earnings ratio is 21.17x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmuCell Corp. is 1.78x versus 3.01x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCCImmuCell Corp.1.78x 21.17x $5.5M -$139.7K NBYNovaBay Pharmaceuticals, Inc.3.01x 2.60x $521K -$1.3M
-
Which has Higher Returns ICCC or OGEN?
Oragenics, Inc. has a net margin of -2.54% compared to ImmuCell Corp.'s net margin of --. ImmuCell Corp.'s return on equity of 8.15% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital ICCCImmuCell Corp.42.92% -$0.02 $43.4M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About ICCC or OGEN?
ImmuCell Corp. has a consensus price target of --, signalling upside risk potential of 155.48%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 104.96%. Given that ImmuCell Corp. has higher upside potential than Oragenics, Inc., analysts believe ImmuCell Corp. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ICCCImmuCell Corp.0 0 0 OGENOragenics, Inc.1 0 0 -
Is ICCC or OGEN More Risky?
ImmuCell Corp. has a beta of 0.200, which suggesting that the stock is 79.986% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock ICCC or OGEN?
ImmuCell Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmuCell Corp. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCC or OGEN?
ImmuCell Corp. quarterly revenues are $5.5M, which are larger than Oragenics, Inc. quarterly revenues of --. ImmuCell Corp.'s net income of -$139.7K is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, ImmuCell Corp.'s price-to-earnings ratio is 21.17x while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmuCell Corp. is 1.78x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCCImmuCell Corp.1.78x 21.17x $5.5M -$139.7K OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns ICCC or PTN?
Palatin Technologies has a net margin of -2.54% compared to ImmuCell Corp.'s net margin of --. ImmuCell Corp.'s return on equity of 8.15% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ICCCImmuCell Corp.42.92% -$0.02 $43.4M PTNPalatin Technologies-- -- -- -
What do Analysts Say About ICCC or PTN?
ImmuCell Corp. has a consensus price target of --, signalling upside risk potential of 155.48%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than ImmuCell Corp., analysts believe Palatin Technologies is more attractive than ImmuCell Corp..
Company Buy Ratings Hold Ratings Sell Ratings ICCCImmuCell Corp.0 0 0 PTNPalatin Technologies0 0 0 -
Is ICCC or PTN More Risky?
ImmuCell Corp. has a beta of 0.200, which suggesting that the stock is 79.986% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock ICCC or PTN?
ImmuCell Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmuCell Corp. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCC or PTN?
ImmuCell Corp. quarterly revenues are $5.5M, which are larger than Palatin Technologies quarterly revenues of --. ImmuCell Corp.'s net income of -$139.7K is higher than Palatin Technologies's net income of --. Notably, ImmuCell Corp.'s price-to-earnings ratio is 21.17x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmuCell Corp. is 1.78x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCCImmuCell Corp.1.78x 21.17x $5.5M -$139.7K PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns ICCC or TOVX?
Theriva Biologics, Inc. has a net margin of -2.54% compared to ImmuCell Corp.'s net margin of --. ImmuCell Corp.'s return on equity of 8.15% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital ICCCImmuCell Corp.42.92% -$0.02 $43.4M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About ICCC or TOVX?
ImmuCell Corp. has a consensus price target of --, signalling upside risk potential of 155.48%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3064.56%. Given that Theriva Biologics, Inc. has higher upside potential than ImmuCell Corp., analysts believe Theriva Biologics, Inc. is more attractive than ImmuCell Corp..
Company Buy Ratings Hold Ratings Sell Ratings ICCCImmuCell Corp.0 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is ICCC or TOVX More Risky?
ImmuCell Corp. has a beta of 0.200, which suggesting that the stock is 79.986% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock ICCC or TOVX?
ImmuCell Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmuCell Corp. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICCC or TOVX?
ImmuCell Corp. quarterly revenues are $5.5M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. ImmuCell Corp.'s net income of -$139.7K is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, ImmuCell Corp.'s price-to-earnings ratio is 21.17x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmuCell Corp. is 1.78x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICCCImmuCell Corp.1.78x 21.17x $5.5M -$139.7K TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
67
GPCR alert for Dec 9
Structure Therapeutics, Inc. [GPCR] is up 102.52% over the past day.
Buy
62
SMX alert for Dec 9
SMX (Security Matters) Plc [SMX] is down 59.64% over the past day.
Buy
90
KYMR alert for Dec 9
Kymera Therapeutics, Inc. [KYMR] is up 41.67% over the past day.
